• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis.

作者信息

Chimenti Maria Sole, Teoli Miriam, Di Stefani Alessandro, Giunta Alessandro, Esposito Maria, Perricone Roberto

出版信息

Eur J Dermatol. 2013 Apr 1;23(2):273-4. doi: 10.1684/ejd.2013.1929.

DOI:10.1684/ejd.2013.1929
PMID:23557629
Abstract
摘要

相似文献

1
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis.类风湿关节炎患者在使用依那西普治疗期间出现的局限性硬皮病经利妥昔单抗治疗后缓解。
Eur J Dermatol. 2013 Apr 1;23(2):273-4. doi: 10.1684/ejd.2013.1929.
2
[Membranous nephropathy secondary to rheumatoid arthritis occurring during anti-TNFalpha therapy and responsive to second-line treatment with rituximab].[抗TNFα治疗期间继发于类风湿关节炎的膜性肾病并对利妥昔单抗二线治疗有反应]
G Ital Nefrol. 2011 Mar-Apr;28(2):214-8.
3
Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.依那西普治疗失败的德国类风湿关节炎患者使用利妥昔单抗治疗的成本效果分析。
Eur J Health Econ. 2010 Feb;11(1):95-104. doi: 10.1007/s10198-009-0205-y. Epub 2009 Dec 5.
4
Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.对抗肿瘤坏死因子-α有反应的日本类风湿性关节炎患者中抗环瓜氨酸肽抗体水平的降低
Mod Rheumatol. 2010 Oct;20(5):528-30. doi: 10.1007/s10165-010-0305-7. Epub 2010 May 12.
5
Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept.信件：1例由依那西普诱发的泛发性点滴状银屑病，在使用阿巴西普后复发。
Dermatol Online J. 2011 Jun 15;17(6):11.
6
Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.利妥昔单抗与依那西普联合治疗类风湿关节炎患者的安全性。
Rheumatology (Oxford). 2009 Apr;48(4):440-1. doi: 10.1093/rheumatology/ken491. Epub 2009 Jan 19.
7
Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.类风湿关节炎患者对单克隆抗体过敏反应的成功快速利妥昔单抗脱敏治疗：一个显著的选择。
J Investig Allergol Clin Immunol. 2011;21(4):319-21.
8
Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab.类风湿关节炎患者在使用依那西普治疗期间发生冷凝集素病，用利妥昔单抗成功治疗。
Rheumatology (Oxford). 2008 May;47(5):734-5. doi: 10.1093/rheumatology/ken076. Epub 2008 Mar 7.
9
Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?与依那西普治疗失败的类风湿关节炎患者相比，初治的类风湿关节炎患者对英夫利昔单抗的反应更好吗？
Ann Rheum Dis. 2004 May;63(5):607-8; author reply 608.
10
[Remission--therapy goal in rheumatoid arthritis].
Z Rheumatol. 2007 Feb;66(1):2 p following 87.

引用本文的文献

1
New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review.青少年硬皮病的新型挑战性全身治疗方法：综述
Pharmaceuticals (Basel). 2025 Apr 28;18(5):643. doi: 10.3390/ph18050643.
2
Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report.阿达木单抗生物类似药治疗后发生硬斑病：1 例病例报告。
Curr Rheumatol Rev. 2024;20(4):451-454. doi: 10.2174/0115733971266803231117072453.
3
Recent Advances in Treatment of Systemic Sclerosis and Morphea.系统性硬皮病和硬斑病治疗的最新进展。
Am J Clin Dermatol. 2024 Mar;25(2):213-226. doi: 10.1007/s40257-023-00831-2. Epub 2023 Dec 12.
4
Systemic sclerosis and rheumatoid arthritis overlap syndrome - management of severe cardiac, pulmonary and articular involvement.系统性硬化症与类风湿关节炎重叠综合征——严重心脏、肺部及关节受累的管理
Reumatologia. 2023;61(1):55-62. doi: 10.5114/reum/161299. Epub 2023 Mar 8.
5
Morphea: The 2023 update.硬斑病：2023年更新版
Front Med (Lausanne). 2023 Feb 13;10:1108623. doi: 10.3389/fmed.2023.1108623. eCollection 2023.
6
Is biological therapy in systemic sclerosis the answer?生物疗法是系统性硬化症的答案吗？
Rheumatol Int. 2020 May;40(5):679-694. doi: 10.1007/s00296-020-04515-6. Epub 2020 Jan 20.
7
Update on the Systemic Treatment of Pediatric Localized Scleroderma.儿童局限性硬皮病的系统治疗进展。
Paediatr Drugs. 2019 Dec;21(6):461-467. doi: 10.1007/s40272-019-00363-5.
8
Autoantibodies in Morphea: An Update.硬斑病中的自身抗体：最新进展。
Front Immunol. 2019 Jul 9;10:1487. doi: 10.3389/fimmu.2019.01487. eCollection 2019.
9
Morphea and Eosinophilic Fasciitis: An Update.硬斑病和嗜酸性筋膜炎：最新进展
Am J Clin Dermatol. 2017 Aug;18(4):491-512. doi: 10.1007/s40257-017-0269-x.
10
Biologics in dermatology: an integrated review.皮肤科生物制剂：综合综述。
Indian J Dermatol. 2014 Sep;59(5):425-41. doi: 10.4103/0019-5154.139859.